PG101 Studies Accepted for Publication

PG101 Studies Accepted for Publication

LOS ANGELES--PanGenomics announced two studies ofits PG101 have been accepted for publication in the peer-reviewed journal ExperimentalBiology & Medicine (www.ebmonline.org).PG101 is a water-soluble extract of the edible mushroom Lentinus lepideus.Both studies were conducted by researchers at Seoul National University in SouthKorea to investigate the extract's immune-enhancing properties.

In the first study, researchers treated human peripheral bloodmononuclear cells with PG101 and witnessed increases in several immune cells,including TNF-alpha, interleukin-1-beta, interleukin-10 and interleukin-12. Theincreases, which occurred up to 1,000-fold, were affected in a dose- andtime-dependent manner. Researchers also found PG101 was non-toxic in rats andhuman blood cells at biological concentrations 20-times greater thanbiologically effective concentrations. Researchers concluded PG101 demonstratedgreat potential as a therapeutic immune modulator and may induce cellular immuneresponses such as antimicrobial and antitumor activity.

In the second study, researchers discovered oral administrationof PG101 may enhance immunity during radiation or chemotherapy. They treatedmice with irradiation and gave some of them PG101 daily for 24 days. The micetreated with the extract exhibited an increase in the number of colony-formingcells that was similar to the levels seen in non-irradiated control animals asearly as eight days after irradiation. Researchers also noted oraladministration of the extract increased serum levels of several immune proteins,including GM-CSF, interleukin-6 and interleukin-1-beta--immune cytokines thoughtto be radio-protective. Researchers concluded PG101 is a potent immune modulatorthat benefits radiation-damaged bone marrow, making it potentially useful inimmunocompromised and immunosuppressed individuals.